Centene CNC
Healthcare · Medical - Healthcare Plans · Synthos Deep Dive · 2026-07-03
The Overview
Centene runs government-funded health-insurance plans — mostly Medicaid (coverage for lower-income families), plus Medicare drug plans and ACA "Obamacare" marketplace plans. It's huge on revenue (~$195 billion) but keeps only a very thin slice as profit — a couple of cents on the dollar in a good year, and it actually posted a loss in 2025 after writing down the value of some past acquisitions.
Is the stock cheap or expensive? Cheap — on cash flow. The company throws off a lot of cash relative to its price (about a 13% cash yield), and it trades at a low multiple of next year's expected earnings. But it's cheap for reasons: its profits swing hard with medical costs and with decisions made in Washington and state capitals.
Our verdict is Watch — interesting, recovering, cheap, but not a table-pounding Buy. The stock already tripled off its bottom, so the bargain is partly gone.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The balance sheet is fine and the price is low, but the business is fragile to government policy and its profit margin is razor-thin, so bad news hits hard. The stock has fallen 30%+ before.
- Growth Quality 4/10 (below average). It's a low-margin, low-return business whose earnings bounce around. This isn't a smooth, high-quality grower.
- Exponential Potential 3/10 (low). Revenue barely grows. The improvement is about fixing profit margins, not exploding sales — so don't expect a rocket.
The one big worry: almost everything depends on government reimbursement — Medicaid payment rates, who stays enrolled, and whether ACA subsidies survive politically. A single adverse policy decision can wipe out a year of profit.
Putting a number on it: our fair-value estimate is $68 against a current price of $64.75 — real upside if our numbers are right.
Our summary metrics
Dirt-cheap on cash flow (13% FCF yield, ~0.1× net-debt/EBITDA) but a GAAP loss year, beta 1.09, −30% drawdown history, and policy risk drives everything.
Low-single-digit net margin, negative TTM GAAP ROE/ROIC, volatile HBR-driven earnings — this is a margin-recovery story, not quality compounding.
Revenue is essentially flat/GDP-like; EPS growth is recovery off a depressed base, not top-line acceleration. No multibagger platform.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Revenue is essentially flat/GDP-like; EPS growth is recovery off a depressed base, not top-line acceleration. No multibagger platform.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $60 (high $80 / low $39; 27 Buy · 15 Hold · 1 Sell) — context, not our anchor |
| Valuation | GAAP loss FY25 (impairment) · ~20× FY26E · 15× FY27E · 11× FY28E · 7.5× FY30E · EV/S 0.14× · P/S 0.17× · P/B 1.6× · 13% FCF yield |
| Technicals | Sharp recovery — $67.86, near 52-wk high, above 50/200-DMA, RSI 61, +170% off the low, but only +20% 12-mo (≈ SPY) |
| Conviction | Low — 0 expert voices in the Synthos KB; call rests entirely on fundamentals + quant |
| Position sizing | Small/tactical only, ~1–2% if taken at all — a value-recovery trade, not a core holding |
What the experts actually said 1 traceable claims on CNC · showing the highest-conviction voices
“Low-margin, labor-heavy firms become big AI winners — a 5% expense cut yields ~20-25% EPS jump; agents deployed as infrastructure unlock margin benefit not yet priced.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $64.75, 1% below the 50-day average ($65), 31% above the 200-day average ($50) — a mixed trend. 6% below the 52-week high of $69, 128% above the 52-week low of $28.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $64.75 is currently inside the band (band $63–$67).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 49.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.07, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = CNC · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Centene Corp. (NYSE: CNC) is a St. Louis–based managed-care company — the largest Medicaid managed-care organization in the US — that administers government-sponsored and subsidized health plans for under-insured and lower-income populations. Founded 1984, IPO'd 2001, ~61,100 employees, led by CEO Sarah London. Fiscal year ends December 31. It reports across Medicaid, Medicare, Commercial (ACA Marketplace), and Other segments.
Revenue mix (from filings):
- By segment (FY2025, FMP product segmentation): Medicaid $147.6B (~76%) · Commercial (Marketplace) $42.0B (~22%) · Other $5.1B. (Note: FY25 total revenue of $194.8B is inflated versus prior years partly by growth/reclassification in the Medicare Part D / PDP business; premium-and-service revenue is the cleaner operating line — see §5.)
- By line of business (Q1'26 premium & service, from the 8-K): Medicaid $23.6B (+6% YoY) · Medicare $10.3B (+18%) · Commercial/Marketplace $9.6B (−6%) · Other $1.2B. The Marketplace decline is the story: membership fell from 5.63M (Q1'25) to 3.58M (Q1'26) as pandemic-era enrollment normalized.
- Geography: US-only (no meaningful international;
seg_geoempty).
The investment question is not "can it grow revenue" (revenue is roughly flat and policy-driven) — it is "can management recover the Health Benefits Ratio (HBR) and restore adjusted EPS toward mid/high-single digits," which is exactly what the 2025 collapse-and-2026 recovery arc is testing.
2. The expert thesis
There is no expert coverage of CNC in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty. No net-bullish or cautionary voice has been distilled for this name.
Accordingly, this verdict is entirely fundamentals- and quant-driven — built from FMP financials, analyst estimates, the company's own SEC 8-K guidance (§9), and the technical/valuation blocks below. We do not manufacture conviction we do not have: with zero traceable claim_ids, there is nothing to cite, and the "conviction" rating is Low by construction. Treat the scores in §3 as a quantitative read, not a crowd-of-experts read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Genuinely cheap (13% FCF yield, ~0.1× net-debt/EBITDA, $17.9B cash) — but FY25 was a GAAP loss on a $6.6B impairment, beta is 1.09, it has drawn down 30%+, and margins/earnings hinge on government reimbursement. Cheap ≠ safe here. |
| Growth Quality | 4 · Below Average | Net margin is low-single-digit in a good year and negative TTM on GAAP; TTM ROE/ROIC are negative on the loss; the moat is contract- and scale-based, not durable pricing power. This is a recovery, not a quality compounder. |
| Exponential Potential | 3 · Low | Revenue is essentially flat/GDP-like; forward EPS growth is margin recovery off a depressed base, not top-line acceleration. A $33.5B cap in a mature, regulated TAM has no multibagger runway. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Margin recovery sticks and accelerates; Medicaid rates catch up to trend, Marketplace stabilizes, Medicare Advantage turns profitable. FY27 adj EPS beats to ~$5.10–5.50 (vs $4.52 cons); modest re-rate to ~15×. | ~$80 (+18%) |
| Base (our anchor) | Recovery roughly on track — management's ">$3.40" FY26 guide holds, FY27 adj EPS ~$4.50; a thin-margin, policy-exposed insurer earns only a ~14–15× multiple. Cash flow supports the floor. | ~$68 (~flat) |
| Bear | Government-policy shock — a Medicaid rate cut, adverse redetermination mix, or ACA-subsidy expiry; HBR re-spikes and EPS stalls near ~$3.50; multiple de-rates to ~10–11×. | ~$40 (−41%) |
Synthos fair value = the base case, ~$68 (roughly at market), with the full $40–$80 span as the honest range. Note how wide that band is (−41% to +18%) — that asymmetry, driven by policy tail risk, is precisely why this is a Watch, not a Buy: the recovery is real but largely priced after a +170% move, and the downside tail is fat. Our base sits above the Street's $60 consensus (we credit FY27 earnings power and the cash flow) while our bear is near the Street's $39 low. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CNC is neither — it is a cyclical margin-recovery / mean-reversion story:
- Forward growth: revenue is roughly flat — FY25 $194.8B → FY30E ~$215B is only ~2%/yr, and even that overstates it (Part D reclass noise). The real engine is EPS recovery: FY26E ~$3.50 → FY30E ~$9.00 is a ~26% EPS CAGR, but that is bounce-back off a crushed 2025 base, not organic acceleration.
- Acceleration (2nd derivative): revenue growth is not accelerating — it is a mature, GDP-plus, policy-capped top line. What's improving is the margin, which is a recovery vector with a ceiling (a good HBR is ~87–88%, leaving ~2–3% net margin at best). Once margins normalize, growth reverts to low-single-digit.
- Room to run: the Medicaid/government-managed-care TAM is large but fully penetrated and regulated — Centene is already #1. At $33.5B cap there is re-rating upside if earnings normalize, but no structural multibagger runway.
- Reinvestment runway: limited — this is a capital-light, low-ROIC contract business that returns cash via buybacks ($475M repurchased FY25, debt paydown $1B in Q1'26) rather than compounding at high rates.
Exponential Potential: Low (3/10). Own CNC — if at all — for cheapness and mean-reversion, not for exponential growth. It is the opposite end of the spectrum from a small accelerating platform.
5. Financials (real numbers — FMP annual/quarterly + the Q1'26 8-K)
- Revenue: FY25 $194.8B (+19% reported, but heavily flattered by Part D/PDP growth & reclassification), FY24 $163.1B, FY23 $154.0B. Cleaner operating line: premium & service revenue $44.7B in Q1'26, +5% YoY.
- The 2025 loss (read this carefully): FY25 GAAP net income was −$6.67B / EPS −$13.61, but that is not the run-rate — it was driven by a ~$6.6B non-cash goodwill impairment in Q3'25 (goodwill fell from $17.6B to $10.8B on the balance sheet). Strip the impairment and the underlying business was modestly profitable-to-breakeven through a bad-cost year.
- The recovery is visible quarter-by-quarter: Q1'25 EPS +$2.64 → Q2 −$0.51 → Q3 −$13.50 (impairment) → Q4 −$2.24 → Q1'26 +$3.11 GAAP / +$3.37 adjusted (beat by ~$0.50). Q1'26 net income $1.54B.
- Health Benefits Ratio (the key margin): consolidated HBR 87.3% in Q1'26 (down from 87.5% Q1'25) — Medicaid 93.1%, Medicare 84.9%, Commercial 75.3%. Every 100bps of HBR is ~$1.8B of pre-tax on this revenue base, so small HBR moves swing earnings violently.
- Cash flow: the real bright spot — FY25 operating CF $5.09B, capex only −$767M, FCF $4.32B (13% FCF yield); Q1'26 operating CF $4.37B. Cash generation is far healthier than the GAAP loss suggests.
- Balance sheet: cash & investments $17.9B, total debt $18.8B, net debt just $0.9B; net-debt/EBITDA ~0.1× on normalized EBITDA. $1.0B of debt reduced in Q1'26. No dividend. Financially sturdy — the risk is the P&L, not solvency.
6. Valuation — priced in or room?
On headline numbers CNC screens cheap: 0.14× EV/sales, 0.17× P/S, 1.6× P/B, ~13% FCF yield. The trailing P/E is meaningless (loss year). The forward picture on consensus: ~20× FY26E ($3.50) → 15× FY27E ($4.52) → 11× FY28E ($6.07) → 7.5× FY30E ($9.00). Managed-care peers historically trade ~12–16× forward earnings, so on FY27 CNC is roughly in line to slightly cheap — the deep-value optics come mostly from the sales and book multiples, which are structurally low for a thin-margin insurer and shouldn't be read as UNH-style bargains.
The honest read: the cheapness is real but conditional. If management delivers the margin recovery (FY26 adj EPS >$3.40, FY27 ~$4.50+), a 14–15× multiple gets you to ~$63–68 — i.e., roughly today's price. The upside requires either a beat or a re-rate; the base case is that the recovery is already substantially in the stock after +170% off the low. Street targets (context): consensus $60, high $80, low $39 (27 Buy / 15 Hold / 1 Sell) — our ~$68 base is modestly above consensus, crediting the cash flow. FMP's letter rating is C+ (overall score 2/5), dinged on ROE/ROA/leverage — consistent with our Growth-Quality 4.
7. Technicals (from the tech block)
- Trend: up, and stretched off the bottom. $67.86 sits above the 50-DMA ($58.62) and well above the 200-DMA ($43.58) — a recovery uptrend. MACD +2.29 (positive).
- Location: essentially at the 52-week high (−0.7% off $68.35) and +169% off the 52-week low ($25.21) — this stock has already tripled from its trough. Max drawdown from peak in the window was −30%, a reminder of how violent the moves are.
- Momentum: RSI(14) 61 — firm but not overbought (<70).
- Relative strength (the nuance): +99.9% 3-mo and +64.7% 6-mo (vs SPY +13.7% / +8.4%) — explosive short-term outperformance — but only +19.8% 12-mo, roughly in line with SPY (+20.6%) and behind QQQ (+30.3%). Translation: nearly all the outperformance is a recent recovery snap-back; on a one-year view it's merely kept pace.
- Read: technicals confirm a recovery that is largely complete in the near term. Chasing at the 52-week high after a triple is poor risk/reward; a pullback toward the rising 50-DMA (~$59) would be a far better entry — reinforcing the Watch stance.
8. Moat & competitive position
Centene's "moat" is scale and government relationships, not pricing power: it is the largest Medicaid managed-care organization in the US, with the state-contract footprint, provider networks, and administrative scale to bid and win government business at low cost. That is a real but defensive and low-margin advantage — contracts are re-bid, rates are set by governments, and a single state loss or rate action can dent a segment. There is no consumer brand or switching-cost moat of the kind a software or medical-device franchise enjoys.
Peer set (FMP-supplied, note the mismatch): the FMP peer list — Fresenius Medical Care, Genmab, Hologic, Illumina, Medpace, Royalty Pharma, Smith & Nephew, Tempus AI, Tenet Healthcare ($17.5B), Universal Health Services ($9.9B) — is a grab-bag of healthcare-services and tools names and is not a clean managed-care comp set. The relevant competitive frame is the government/managed-care group (UnitedHealth, Elevance, Molina, CVS/Aetna) against which Centene is the Medicaid scale leader but the lowest-margin, most-policy-exposed of the majors. Treat the FMP peers as sector context only.
9. Management, capital allocation & guidance
- Capital allocation: cash-return + de-lever, not empire-building — FY25 bought back $475M of stock, reduced debt $1.0B in Q1'26, no dividend. Appropriate for a low-ROIC business in recovery: fix the margin and pay down debt before returning more.
- Insider activity: the recent Form 4s are almost all routine director stock awards (2026-06-30, price $0). One notable open-market sale: director Kenneth Burdick sold 80,000 shares at $64.55 on 2026-06-10, and COO Susan Smith had a small in-kind (tax-withholding) disposition — worth noting a director selling into the recovery, but not a broad insider-selling cluster.
- Management's own guidance (half-weighted — their self-interested words): the SEC 8-K (Q1'26 earnings release, 2026-04-28) is a real earnings release and states management's forward guidance plainly. CEO Sarah London: Q1 adjusted EPS of $3.37 was "approximately $0.50 better than our expectations," and on the strength of it the company raised full-year 2026 guidance to GAAP diluted EPS ">$2.37" and adjusted diluted EPS ">$3.40." Management cites "tangible progress in margin recovery," Medicaid HBR of 93.1% improving on rate/cost actions, and Medicare Advantage "progression towards profitability." Weighting: this is management talking its own book — half-weight it — but the direction (raised guide, HBR improving, MA turning) is corroborated by the actual Q1'26 print, which lends it more credibility than a pure forward promise.
10. Catalysts & what to watch
- Next earnings: 2026-07-28 (Q2'26; Street EPS $1.06, revenue ~$47.6B). The key lines: consolidated and Medicaid HBR (is the margin recovery holding?), Marketplace membership trajectory, and any reaffirmation/raise of the ">$3.40" FY26 adjusted-EPS guide.
- Medicaid rate cycle: state rate updates vs. medical-cost trend — the single biggest earnings swing factor.
- ACA Marketplace / subsidy policy: enhanced premium-tax-credit expiry and enrollment normalization — Commercial membership already −36% YoY; further erosion or a subsidy cliff hits the Commercial segment.
- Medicare Advantage profitability: management claims "progression towards profitability" — watch for confirmation.
- Redetermination tail: ongoing Medicaid redetermination mix (acuity of the remaining pool) driving HBR.
Thesis tripwires (what would change the call): consolidated HBR re-accelerating above ~89–90%; a withdrawn or cut FY26 guide; a materially adverse federal Medicaid or ACA-subsidy action; or FCF failing to sustain (it is the floor under the value case).
11. Key risks
- Government-policy dependence (structural, the dominant risk): Medicaid rates, redetermination, and ACA-subsidy politics set the P&L. This is the reason for the wide fair-value band and the Watch verdict.
- Thin-margin fragility: ~2–3% net margin at best means small HBR moves swing earnings violently — the business has little buffer.
- Earnings quality / GAAP loss: FY25 posted a GAAP loss on a $6.6B impairment; reported ROE/ROIC are negative TTM. The recovery is early and unproven beyond one strong quarter.
- Marketplace membership erosion: Commercial membership −36% YoY (5.63M → 3.58M) — a shrinking, higher-risk pool.
- No expert corroboration: zero Synthos KB coverage — the thesis has no independent-analyst signal behind it, only quant/fundamentals.
- Momentum risk: the stock has tripled off its low and sits at the 52-week high — late to a completed recovery move.
12. Verdict, position sizing & monitoring
Watch. Centene is a genuinely cheap (13% FCF yield, 0.14× EV/sales), financially sturdy (net debt ~$0.9B) Medicaid leader whose margin recovery is real and visible — Q1'26 adjusted EPS beat by ~$0.50 and management raised the FY26 adjusted-EPS guide to ">$3.40." But the earnings are thin-margin, policy-hostage, and GAAP-negative in the trailing year; there is no expert coverage to corroborate the call; and the stock has already tripled off its low to sit at its 52-week high, so most of the easy recovery is priced. Base-case fair value ~$68 is roughly today's price, with a fat −41% bear tail driven by policy risk. That asymmetry is a Watch, not a Buy.
- Sizing: if taken at all, small/tactical (~1–2%) as a value-recovery trade — not a core holding. Prefer to add on a pullback toward the rising 50-DMA (~$59) rather than chase the 52-week high.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-07-28 print, focused on HBR and the FY26 guide. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $67.86.
- Single biggest risk: a government-reimbursement or ACA-subsidy shock — Washington and state capitals hold the pen on this P&L.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert voices exist for CNC in the Synthos knowledge base, so no
claim_ids are cited. This is disclosed, not hidden: the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (nothing to reconcile). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K dated 2026-04-28. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: the ">$3.40" FY26 adjusted-EPS figure is management's own guidance, half-weighted by design — corroborated by, but not independent of, the Q1'26 print.
- Modeling note: FY25 GAAP EPS of −$13.61 reflects a ~$6.6B non-cash goodwill impairment (Q3'25) and is not run-rate; valuation and scores are anchored to adjusted/forward earnings and cash flow.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").